Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.400 -0.030 (-2.10%)

Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Allogene (ALLO) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations.

Via The Motley Fool

Topics Earnings

Allogene Therapeutics Q2 Earnings Call Highlights ↗

August 12, 2026

Allogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3...

Via MarketBeat

Topics Earnings

Allogene Therapeutics Q1 Earnings Call Highlights ↗

May 13, 2026

Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April...

Via MarketBeat

Topics Earnings

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts ↗

March 12, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Allogene (ALLO) Q1 2026 Earnings Transcript ↗

May 13, 2026

Allogene (ALLO) Q1 2026 Earnings Transcript

Via The Motley Fool

Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗

May 13, 2026

Via Benzinga

Topics Earnings

Thursday's session: gap up and gap down stocks ↗

April 16, 2026

Via Chartmill

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 14, 2026

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.

Via Benzinga

These stocks are making the most noise in today's session. ↗

April 13, 2026

Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

Via Chartmill

Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗

April 13, 2026

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.

Via Benzinga

These stocks are gapping in today's session ↗

April 13, 2026

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗

April 13, 2026

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.

Via Benzinga

Topics Stocks

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Get insights into the top gainers and losers of Friday's after-hours session. ↗

April 10, 2026

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗

March 12, 2026

Allogene (ALLO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗

January 21, 2026

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.

Via The Motley Fool

Topics Stocks

The market is filled with gapping stocks in Friday's session. ↗

January 09, 2026

Via Chartmill

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

Via The Motley Fool

Topics Death Regulatory Compliance

What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗

December 26, 2025

A patient, partnership-driven family office didn’t wait for fundamentals to break before walking away, and that timing may matter more than the sale itself.

Via The Motley Fool

Topics Death Regulatory Compliance

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗

December 16, 2025

Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.

Via Benzinga

The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance

December 04, 2025

Washington D.C. – December 4, 2025 – A persistent and increasingly vocal debate continues to plague the halls of Congress, centering on allegations that elected officials are leveraging their unique...

Via MarketMinute

Topics Bonds ETFs World Trade

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗

November 06, 2025

Allogene Therapeutics beat Q3 2025 earnings estimates with a narrower loss and reaffirmed its cash runway into 2027. The biotech also reported progress on its allogeneic CAR T pipeline.

Via Chartmill

Topics Earnings

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...

Via MarketMinute

Topics Initial Public Offering Regulatory Compliance Workforce

This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

October 10, 2025

Via Benzinga

Allogene Q2 Cash Tops $300 Million ↗

August 13, 2025

Via The Motley Fool

Allogene Narrows Loss in Fiscal Q2 ↗

August 13, 2025

Via The Motley Fool

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗

August 13, 2025

Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress.

Via Chartmill

A Look at Allogene Therapeutics's Upcoming Earnings Report ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.